Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Kobayashi, Miwako; Farrar, Jennifer L.; Gierke, Ryan; Britton, Amadea; Childs, Lana; Leidner, Andrew J.; Campos‐Outcalt, Doug; Morgan, Rebecca L.; Long, Sarah S.; Talbot, H. Keipp; Poehling, Katherine A.; Pilishvili, Tamara

doi:10.15585/mmwr.mm7104a1

articleMMWR Morbidity and Mortality Weekly ReportJan 27, 2022DIAMOND OA

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MKMiwako Kobayashi JLJennifer L. Farrar RGRyan Gierke ABAmadea Britton LCLana Childs

Center for Surveillance, Epidemiology, and Laboratory Services

PubMed

Indexed incrossrefpubmed

Abstract

Approach to guide its deliberations regarding use of these vaccines. Before this, PCV13 and PPSV23 were recommended for use for U.S. adults and the recommendations varied by age and risk groups. This was simplified in the new recommendations.

Citation impact

339

total citations

FWCI: 50.47
Percentile: 100%
References: 32

Citations per year

Authors

12

Topics & keywords

Topics

Keywords

Pneumococcal conjugate vaccine
Medicine
Pneumococcal polysaccharide vaccine
Advisory committee
Vaccination
Immunization
Food and drug administration
Conjugate vaccine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.